The week in pharma: action, reaction and insight - week to November 5, 2021
By Barbara Obstoj-Cardwell
Deal-making news last week featured US pharma giant Merck & Co further expanding its cytokines portfolio, signing a license and research collaboration with Synthekine on novel therapeutics for autoimmune diseases. Also, Swiss giant Novartis extended its interest in the area of protein degraders, announcing an up to $1.3 billion deal with Dunad Therapeutics. Long rumored and finally announced, Novartis said it has agreed to sell back to Roche the 33% of voting shares it has been holding in its Swiss rival for 20 years or so. Meantime, Pfizer, already preeminent in the COVID-19 sector with its hugely successful vaccine Comirnaty, released very positive Phase II/III trial results for its antiviral Paxlovid (ritonavir).
Merck dives even further into cytokine research as deal spree continues
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze